KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Change in Account Payables (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Change in Account Payables data on record, last reported at -$2.2 million in Q4 2025.

  • For Q4 2025, Change in Account Payables fell 106.38% year-over-year to -$2.2 million; the TTM value through Dec 2025 reached $931000.0, down 98.29%, while the annual FY2025 figure was $931000.0, 98.29% down from the prior year.
  • Change in Account Payables reached -$2.2 million in Q4 2025 per AMRX's latest filing, roughly flat from -$2.2 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $34.1 million in Q4 2024 and bottomed at -$7.2 million in Q2 2021.
  • Average Change in Account Payables over 5 years is $3.2 million, with a median of $1.7 million recorded in 2021.
  • Peak YoY movement for Change in Account Payables: soared 3526.67% in 2021, then crashed 6605.33% in 2022.
  • A 5-year view of Change in Account Payables shows it stood at $1.6 million in 2021, then plummeted by 124.94% to -$407000.0 in 2022, then surged by 1493.61% to $5.7 million in 2023, then surged by 501.23% to $34.1 million in 2024, then plummeted by 106.38% to -$2.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were -$2.2 million in Q4 2025, -$2.2 million in Q3 2025, and $6.4 million in Q2 2025.